Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden · Delayed Price · Currency is SEK 6.26
-0.32 (-4.86%)
Nov 3, 2026, 5:29 PM CET
Annexin Pharmaceuticals AB Earnings Call Transcripts
Fiscal Year 2026
-
Annexin is advancing an intravenous therapy for RVO and diabetic retinopathy, showing unique, sustained improvements in retinal blood flow and a strong safety profile. Ongoing trials are testing combination regimens, with regulatory and licensing efforts focused on the US and global markets.
Fiscal Year 2025
-
A novel protein therapy for retinal vein occlusion and diabetic retinopathy shows rapid, durable effects and could significantly reduce the need for costly anti-VEGF injections. Phase 2A results have impressed US key opinion leaders, and a phase 2B trial is planned, with the US market as the initial focus.